Configurable Analysis Across Neuroscience Research
Research Applications Across Brain Health and Neurotechnology
Neuromap™ is a configurable analytical platform rather than a single-condition test. Appropriate variables, reference comparisons and interpretation depend on the research question, participant population, acquisition protocol and study design.
Parkinson’s disease and movement disorders
Potential research domains include resting-state spectral characteristics, peak-frequency measures, beta-related activity, motor-network organisation, regional balance, functional connectivity, cognitive-motor relationships, fatigue and longitudinal change. Neuromap™ can support healthy-volunteer comparator studies, repeated assessments, medication-state research and intervention-evaluation designs where the protocol supports the proposed variables.
- Baseline and repeat-visit quantitative profiles.
- Motor and non-motor subgroup comparisons.
- Candidate target-engagement and pharmacodynamic variables.
- Medication-state or intervention-phase comparison.
- Longitudinal relationship with approved motor, cognitive or patient-reported outcomes.
Neuromap™ does not diagnose Parkinson’s disease and does not replace neurological assessment.
Alzheimer’s disease, dementia and cognitive ageing
Potential research domains include slowing, peak-frequency characteristics, posterior activity, complexity, network organisation, connectivity, state stability and longitudinal cognitive-neurophysiology relationships. Research designs may examine healthy ageing, subjective cognitive concerns, mild cognitive impairment, dementia cohorts, risk-enriched samples or intervention effects.
Psychiatry and psychopharmacology
Potential research domains include arousal-related frequency characteristics, regional balance, connectivity, complexity, treatment-related change and exploratory responder analysis. Neuromap™ can support depression, anxiety, psychosis, attention, obsessive-compulsive and other protocol-defined research without using EEG outputs as a standalone psychiatric diagnosis.
Healthy-volunteer and early-phase research
Standardised healthy-volunteer environments are well suited to repeated EEG schedules. Neuromap™ can support baseline stability, pre-dose and post-dose analysis, dose-escalation, crossover designs, time-course evaluation, test-retest research, vigilance and cognitive-performance studies. Timing, participant state, sleep, caffeine, medication, task conditions and recording consistency should be prospectively controlled.
Neurodevelopmental research
Potential domains include age-referenced spectral profiles, regional balance, connectivity, temporal dynamics, sensory research variables, attention-related measures and longitudinal developmental change. Paediatric studies require developmentally appropriate acquisition, consent or assent, safeguarding, state control and careful management of motion and sensory burden.
Sleep, fatigue and vigilance
Potential research domains include state-dependent frequency characteristics, transitions, stability, fatigue, attention, sleep-related change and performance relationships. Study interpretation must distinguish resting wake EEG, sleep EEG, task EEG and subjective fatigue measures.
Cognition and performance research
Neuromap™ can support studies of attention, processing speed, executive function, cognitive load, learning, fatigue and performance through predefined resting-state or task-linked EEG variables. Claims must remain proportionate to the design and validated outcome measures.
Neuromodulation, rehabilitation and Research Enhancement Programmes
Neuromap™ can support baseline mapping, target-related hypotheses, pre-intervention and post-intervention comparison, repeated assessment, regression monitoring and longitudinal outcome analysis within ethically approved programmes. The service can be applied to neuromodulation research, rehabilitation, cognitive training, digital therapeutics, behavioural programmes, sleep optimisation, exercise and other enhancement-focused studies.
- Define candidate neurophysiological outcomes before intervention.
- Compare observed change against baseline variability and control conditions where available.
- Identify preserved, improved, unchanged and newly abnormal domains.
- Examine whether EEG-derived change transfers to functional outcomes.
- Generate evidence-based recommendations for replication or protocol refinement without prescribing clinical treatment.
Medical-device and digital-therapeutic research
Device and digital-therapeutic teams can use Neuromap™ to investigate feasibility, neurophysiological change, candidate target engagement, usability-related artefacts and longitudinal outcomes. Regulatory intended purpose, device status, clinical investigation requirements and claims remain the responsibility of the sponsor and must be defined separately.
Choose the application, then define the method
A therapeutic area does not determine a fixed analysis package. Neuromap™ first reviews the study question and acquisition design, then identifies the analyses that are technically supported and scientifically defensible. This prevents irrelevant output volume from replacing a focused research plan.
Frequently asked questions
Common questions about Neuromap™ research applications.
Does Neuromap™ diagnose any of the conditions listed on this page?
No. These are research application areas. Neuromap™ outputs do not replace clinical diagnosis or specialist assessment.
Can the same analysis package be used for every condition?
No. Analysis selection depends on the research hypothesis, acquisition, population, confounders and outcome plan.
Can you compare an intervention group with controls?
Yes, where the data, design and approved analysis plan support the comparison. Biostatistical analysis should be conducted or overseen by appropriately qualified personnel.
Can you support a new therapeutic area not listed here?
Potentially. Feasibility is assessed from the research question, EEG design, data quality and required outputs rather than the diagnostic label alone.